Medicenna Therapeutics Corp. (MDNA.TO)
Develops engineered immune proteins to treat cancer and inflammatory diseases.
0.36+0.03%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-57.7%
The outlook
MDNA.TO is trading near its 52-week lows, well below both its 50- and 200-day averages. Analyst coverage shows a wide gap, with the average price target sitting roughly 8× the current price, though this reflects very thin consensus. The overall sentiment currently leans bearish.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range1% of the way from its 52-week low to high
Price targetAvg target +801% vs current price
Analyst price target
~12-month · 3 analysts3.20average target+801.4% vs now
Now 0.36
Low 1.60High 4.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$32.8M
52-wk high
1.97
52-wk low
0.34
50-day avg
0.40
200-day avg
0.82
Trailing P/E
—